Leading cancer research organizations to host international cancer immunotherapy conferenceAugust 03, 2015
NEW YORK - The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept. 16-19, 2015.
Titled "Translating Science into Survival," the meeting will cover all areas of inquiry in cancer immunology and immunotherapy, including: immune regulation of T-cell responsiveness, genomic methods for identifying tumor antigens, the tumor microenvironment, T-cell therapies, checkpoint blockade, biomarkers, combinations, and the microbiome. More than 60 talks by acknowledged leaders in these areas will be given.
The full program is available here: http://www.aacr.org/Meetings/Pages/Program-Detail.aspx?EventItemID=54&ItemID=149.
Registration is complimentary for credentialed news media. Members of the media can register using this form: http://www.aacr.org/Documents/15Immuno_RegForm.pdf. Return completed forms to Lauren Riley via email at firstname.lastname@example.org or via fax at 215-446-7291.
Public information officers at medical institutes and cancer centers can also register by contacting Lauren Riley at email@example.com or 215-446-7155.
Those following on social media can join the conversation on Twitter at #cicon15.
American Association for Cancer Research
Related Immunotherapy Articles:
By comparing variations in protein expression in tumor samples from a single melanoma patient, researchers from the Johns Hopkins Bloomberg~Kimmel Institute and the Memorial Sloan-Kettering Cancer Center say their findings have the potential to reveal some of the mechanisms underlying response or resistance to immunotherapy drugs.
Scientists have discovered a new type of immune cell that could predict which lung cancer patients will benefit most from immunotherapy treatment, according to a Cancer Research UK funded study* published today (Monday) in Nature Immunotherapy.
Results of a new clinical study establish particular genetic defects in tumors as clinical indicators for successful response to a type of immunotherapy called PD-1 blockade.
Scientists at Johns Hopkins have created a nanoparticle that carries two different antibodies capable of simultaneously switching off cancer cells' defensive properties while switching on a robust anticancer immune response in mice.
Malignant pleural mesothelioma or MPM is a rare cancer, but its incidence has been rising.
Scientists at the University of Basel in Switzerland have, for the first time, described a new T cell population that can recognize and kill tumor cells.
Duke University researchers found that a molecule called PD-L1, which is blocked by the immunotherapy drug nivolumab, acts not only on immune cells but also on the nerve cells that signal pain.
The preparations that are used for allergen immunotherapy against bee sting allergies do not always contain all the relevant venom components.
A noninvasive PET imaging method that measures granzyme B, a protein released by immune cells to kill cancer cells, was able to distinguish mouse and human tumors that responded to immune checkpoint inhibitors from those that did not respond early in the course of treatment.
In lung cancer patients who were taking immunotherapy drugs targeting the PD-1 pathway, testing for CD8 T cell activation in their blood partially predicted whether their tumors would shrink.
Related Immunotherapy Reading:
Curing Cancer with Immunotherapy: How it happened a century ago, what we learned as we attempted it, and why it is possible today.
by Rene Chee (Author), Edward Chee (Author)
Four out of every ten people will be diagnosed with cancer sometime during their lifetime. 600,000 cancer patients in the U.S. will die every year.
For decades, standard therapies have remained powerless against advanced cancer. But in the 1890s, an American surgeon showed that terminal patients could be cured by stimulating their immune systems. The treatment? A concoction of dead bacteria known as Coley’s Toxins.
This is the real-life story of Rene Chee, a biologist diagnosed with an aggressive cancer while working at Stanford University. After conventional treatment, she realizes... View Details
Cancer Immunotherapy Principles and Practice
by Lisa H. Butterfield PhD (Editor), Howard L. Kaufman MD FACS (Editor), Francesco M. Marincola MD FACS (Editor)
“Drs. Butterfield, Kaufman and Marincola on behalf of the SITC have created a comprehensive must-have resource covering the basic and translational science behind approved and investigational immune therapies, and disease-by-disease clinical application of the therapies, written by leaders in the field. The textbook will be highly valuable reading for those just entering the field and for experienced scientists and clinicians looking to expand their knowledge base.” ―Mario Sznol, MD, Professor of Medicine (Medical Oncology), Yale School of Medicine, New Haven,... View Details
A Cure Within: Scientists Unleashing The Immune System to Kill Cancer
by Neil Canavan (Author)
The way we treat cancer is about to change forever. This revolution--and it is precisely that--was sparked not by the invention of a new drug, but by the evolution of an entirely new way of thinking about and managing cancer. Going forward, doctors will not use pharmaceuticals to attack tumors--not directly. Rather, the oncologist will treat the patient's immune system with a drug, and then the patient will treat the tumor.
Based entirely on interviews with the investigators, this book is the story of the immuno-oncology pioneers. It's a story of failure, resurrection, and success.... View Details
Cancer Immunotherapy, Second Edition: Immune Suppression and Tumor Growth
by George C. Prendergast (Editor), Elizabeth M. Jaffee (Editor)
There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer, and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumor immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic... View Details
The Living Cure: The Promise of Cancer Immunotherapy
by Dr. David Eifrig Jr. (Author), The Stansberry Research Team (Author)
In The Living Cure, you'll find out: - A real, science-backed alternative to poisonous chemotherapy and radiation. - Where to go if anyone you know is faced with this horrible disease. - How to access incredible treatments not available to the general public. - One decision that could instantly double your chance of survival. - And much more... Dr. David Eifrig, Jr. is certain this research could save your life or the life of a loved one. View Details
The Low Dose Immunotherapy Handbook: Recipes and Lifestlye Advice for Patients on LDA and EPD Treatment
by Nicolette M Dumke (Author)
The Low Dose Immunotherapy Handbook: Recipes and Lifestyle Tips for Patients on LDA and EPD Treatment gives 90 recipes for patients on low dose immunotherapy treatment for their food allergies. These recipes are for the basic shot time (EPD) diet and the very mixed diet, and include baked goods, main dishes, and side dishes as well as allowable snacks, desserts and treats that make these diets more livable. It also includes organizational information to help you get ready for your shots and sources of special foods and products that low dose immunotherapy patients need. View Details
Immunotherapy (Advances in Experimental Medicine and Biology)
by Aung Naing (Editor), Joud Hajjar (Editor)
In the last decade, immunotherapy has revolutionized the practice of medicine in the field of oncology. This book, Immunotherapy, highlights the immunotherapeutic approaches currently in use and strategies to overcome the associated challenges. As comprehensive knowledge of basic immunology in the context of tumor biology is required to move further along the line of development in translational science, this book provides an overview of the cellular components of the immune system that interact with each other to provide a successful immune response.Immunotherapy offers promising... View Details
Immunotherapy of Cancer: An Innovative Treatment Comes of Age
by Yoshiyuki Yamaguchi (Editor)
This timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recognition, valuable modalities, clinical trials and guidance, personalization, and biomarkers, all of which are essential for understanding the success of cancer immunotherapy. This innovative therapy has been investigated worldwide as the fourth line of cancer treatment after the standard... View Details
Peptide Immunotherapy: Colostrum, A Physician's Reference Guide
by Andrew M. Keech (Author)
For thousands of years raw colostrum has been consumed to help with all sorts of health challenges. In recent years with the use of modern manufacturing techniques, the benefits of consuming raw colostrum have been preserved in powdered colostrum. In the last ten years more advanced fractionation technologies have allowed the large-scale production of liquid colostrum supplements. Now we are observing a revival in the use of colostrum liquids and powders. Colostrum Peptides, more commonly known as Proline-rich Polypeptides (PRPs) are isolated in these liquid colostrum products. Peptide... View Details
Melanoma without a Cause: How the New Miracle Immunotherapy Drugs and My Own Immune System Helped Me Fight Stage Four Cancer
by Bryant Wieneke (Author)
Melanoma without a Cause: How the New Miracle Immunotherapy Drugs and My Own Immune System Helped Me Fight Stage Four Cancer is a tale of survival following a devastating diagnosis of metastatic melanoma. Fighting through some heavy side effects, the author is saved by a treatment not available even a few years ago. He is given immunotherapy drugs, which stimulate his immune system to target and destroy the cancer cells that have spread throughout his body. Melanoma with a Cause chronicles the author’s treatment and remarkable turnaround, but remission remains elusive. A blog has been... View Details